The cost of these medications [to insurers], often ranging from $950 to $1,400 per month, has proven unsustainable and contributes significantly to rising premiums for individuals, employers, and the Commonwealth, said Lora Pellegrini, president of the Massachusetts Association of Health Plans, which represents Point32Health and about a dozen other insurers
Is it normal to feel tired during the first week of Ozempic treatment
Idaho smaller market meant fewer absolute dollars at stake, but the percentage increases in GLP-1 spending were comparable to larger states
Experience a soothing glow-up from the comfort of your home with Alma LMNT
Doweiko JP, Nompleggi DJ
Regulatory Status and FDA Approval Timeline Current FDA Status (as of June 2026) The FDA has not approved retatrutide for any indication as of June 2026